Article Text
Abstract
Aims: To evaluate efficacy and safety in patients with ocular hypertension or open angle glaucoma changed to latanoprost/timolol fixed combination (LTFC).
Methods: A prospective, multicentre, historical control in which qualified patients had their previous therapy substituted by LTFC and were followed for at least 2 months.
Results: In 1676 patients LTFC was continued in 93% throughout the observation period. In all patients LTFC reduced the intraocular pressure (IOP) from 20.6 (SD 3.8) to 17.7 (3.0) mm Hg (p<0.001) compared to previous monotherapies including latanoprost, timolol, α agonists or carbonic anhydrase inhibitors (CAI). LTFC provided more efficacy after changing from adjunctive therapies including: a β blocker added to either CAI, α agonist, or pilocarpine, or CAI added to an α agonist, or latanoprost added to either CAI, α agonist, or β blocker (unfixed combination), and travoprost added to timolol (p<0.007). LTFC was as effective as latanoprost used with dorzolamide/timolol fixed combination (−0.9 mm Hg, p = 0.1792). The most common reason to discontinue therapy was lack of efficacy (n = 70, 4%) and adverse event (n = 17, 1%).
Conclusion: In a clinical setting, patients who have their monotherapy or adjunctive therapy substituted with LTFC may experience reduced IOP, good tolerability, and continuation of therapy for the first 2–3 months of treatment.
- CAI, carbonic anhydrase inhibitors
- IOP, intraocular pressure
- LTFC, latanoprost/timolol fixed combination
- glaucoma
- latanoprost/timolol maleate fixed combination
- CAI, carbonic anhydrase inhibitors
- IOP, intraocular pressure
- LTFC, latanoprost/timolol fixed combination
- glaucoma
- latanoprost/timolol maleate fixed combination
Statistics from Altmetric.com
Footnotes
-
This study was sponsored by Pfizer GmbH, Erlangen, Germany.